Forest Lexapro launch
This article was originally published in Pharmaceutical Approvals Monthly
Forest will launch its antidepressant Lexapro (escitalopram) Sept. 5 at a slight discount to parent drug Celexa. FDA cleared the single-isomer follow on to citalopram Aug. 14. Labeling reports greater potency than Celexa in terms of inhibition of 5-HT reuptake, and Forest says the 10 mg recommended starting dose was shown to be comparable to Celexa 40 mg. The firm is highlighting early relief with Lexapro, although labeling does not include onset of action data. The Lexapro NDA was submitted March 23, 2001, and deemed "approvable" Jan. 25. Forest will stop sampling and promotion of Celexa, which loses exclusivity in January 2004 after a six-month pediatric extensio
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.